LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Novartis AG

Novartis AG

Suletud

116.68 0.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

116.6

Max

116.9

Põhinäitajad
By Trading Economics
Sissetulek	2.7B
Müük	344M 12B
P/E Sektori keskmine	23.59 103.001
Aktsiakasum	1.31
Kasumimarginaal	22.178
EBITDA	4.7B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+0.21 upside

Turustatistika
By TradingEconomics
Turukapital	818M 247B
Eelmine avamishind	116.52
Eelmine sulgemishind	116.68

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

116.33 / 119.15 Toetus ja vastupanu

Novartis AG Graafik

Seotud uudised

26. aug 2024, 09:47 UTC

Omandamised, ülevõtmised, äriostud

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

18. juuli 2024, 05:58 UTC

Tulu

Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update

18. juuli 2024, 05:42 UTC

Tulu

Novartis Raises Profit Guidance as Key Drugs Boost Sales

5. juuni 2024, 15:26 UTC

Omandamised, ülevõtmised, äriostud

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

3. sept 2024, 14:07 UTC

Market Talk

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19. aug 2024, 13:36 UTC

Market Talk

Novartis Well on Track to Achieve Guidance -- Market Talk

14. aug 2024, 09:02 UTC

Market Talk

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18. juuli 2024, 11:55 UTC

Tulu

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18. juuli 2024, 09:40 UTC

Market Talk

Tulu

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18. juuli 2024, 08:45 UTC

Market Talk

Tulu

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

18. juuli 2024, 07:48 UTC

Market Talk

Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk

18. juuli 2024, 07:01 UTC

Market Talk

Tulu

Novartis Profit Outlook Lift Reflects Blockbuster Drug Sales Boost, Operational Execution -- Market Talk

18. juuli 2024, 05:18 UTC

Tulu

Correct: Novartis 2Q Core Operating Profit $4.95B

18. juuli 2024, 05:03 UTC

Tulu

Novartis Had Seen Net Sales to Grow High-Single to Low Double-digit in 2024

18. juuli 2024, 05:03 UTC

Tulu

Novartis Net Sales Guidance in 2024 Unchanged

18. juuli 2024, 05:03 UTC

Tulu

Novartis Had Seen Core Operating Income to Grow Low Double-Digit to Mid-Teens in 2024

18. juuli 2024, 05:03 UTC

Tulu

Novartis Expects Core Operating Income to Grow Mid- to High Teens in 2024

18. juuli 2024, 05:02 UTC

Tulu

Novartis Raises 2024 Guidance

18. juuli 2024, 05:01 UTC

Tulu

Analysts Had 2Q Core Operating Profit at $4.67B

18. juuli 2024, 05:01 UTC

Tulu

Analysts Had 2Q Sales at $12.22B

18. juuli 2024, 05:01 UTC

Tulu

Novartis 2Q Sales $12.51B

18. juuli 2024, 05:01 UTC

Tulu

Novartis 2Q Core Operating Profit $12.51B

18. juuli 2024, 05:00 UTC

Tulu

Novartis AG 2Q EPS $1.60

18. juuli 2024, 05:00 UTC

Tulu

Novartis AG 2Q Adj EPS $1.97

18. juuli 2024, 05:00 UTC

Tulu

Novartis AG 2Q Net Pft $3.2B

20. juuni 2024, 06:35 UTC

Omandamised, ülevõtmised, äriostud

MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q

20. juuni 2024, 06:34 UTC

Omandamised, ülevõtmised, äriostud

Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May

20. juuni 2024, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders

20. juuni 2024, 06:32 UTC

Omandamised, ülevõtmised, äriostud

Novartis Holds Around 91.04% of MorphoSys as of Thursday

20. juuni 2024, 06:31 UTC

Omandamised, ülevõtmised, äriostud

Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders

Võrdlus sarnastega

Hinnamuutus

Novartis AG Prognoos

Hinnasiht

By TipRanks

0.21% tõus

12 kuu keskmine prognoos

Keskmine 116.9 USD 0.21%

Kõrge 125 USD

Madal 97 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Novartis AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Novartis AG aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

116.33 / 119.15Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.